TY  - GEN
AU  - Santos,C
AU  - Azuara,D
AU  - Viéitez,J M
AU  - Páez,D
AU  - Falcó,E
AU  - Élez,E
AU  - López-López,C
AU  - Valladares,M
AU  - Robles-Díaz,L
AU  - García-Alfonso,P
AU  - Bugés,C
AU  - Durán,G
AU  - Salud,A
AU  - Navarro,V
AU  - Capellá,G
AU  - Aranda,E
AU  - Salazar,R
TI  - Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial
SN  - 1569-8041
PY  - 2020///0612
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Biomarkers, Tumor
KW  - genetics
KW  - Camptothecin
KW  - Class I Phosphatidylinositol 3-Kinases
KW  - Colorectal Neoplasms
KW  - drug therapy
KW  - Fluorouracil
KW  - GTP Phosphohydrolases
KW  - Genotype
KW  - Humans
KW  - Leucovorin
KW  - Male
KW  - Membrane Proteins
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Panitumumab
KW  - Prospective Studies
KW  - Proto-Oncogene Proteins B-raf
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Survival Rate
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdz082
ER  -